State Key Laboratory of Bioelectronics, Southeast University, Nanjing.
Clinical Laboratory, Yixing Tumor Hospital, Yixing, China.
J Mol Diagn. 2021 Jan;23(1):46-60. doi: 10.1016/j.jmoldx.2020.10.004. Epub 2020 Oct 27.
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease Cas9 (Cas9) has high specificity to its target DNA as a gene editing tool. This characteristic makes it useful for DNA detection. Combining the advantages of CRISPR/Cas9 and PCR, this study establishes a novel CRISPR/Cas9-based DNA detection method, named CRISPR/Cas9-typing PCR version 4.0 (ctPCR4.0). This method can detect target DNA in one pot with high specificity and sensitivity. In a homogenous reaction, the target DNA is first cleaved by a pair of Cas9- single-guide RNA complexes and thus releases two single strands with free 3' ends, allowing a pair of oligonucleotides to anneal with the strands. The annealed oligonucleotides provide templates for DNA polymerization from the free 3' ends. A universal primer annealing site is thus produced at the end of two single strands. The target DNA is then amplified by PCR using a universal primer. This method was first verified by accurately detecting the cloned L1 fragments of 10 genotypes of high-risk human papilloma viruses (HPVs). This method was then validated by detecting the L1 fragments of two highest-risk HPVs, HPV 16 and HPV 18, in the genomic DNA of two HPV-positive cervical carcinoma cells, HeLa and SiHa. Finally, this method was further validated by accurately detecting 10 high-risk HPVs in 30 clinical samples.
成簇规律间隔短回文重复序列 (CRISPR)/CRISPR 相关内切酶 Cas9 (Cas9) 作为一种基因编辑工具,对其靶 DNA 具有高度特异性。这一特性使其在 DNA 检测中具有应用价值。本研究结合 CRISPR/Cas9 和 PCR 的优势,建立了一种新型的基于 CRISPR/Cas9 的 DNA 检测方法,命名为 CRISPR/Cas9 分型 PCR 第 4.0 版 (ctPCR4.0)。该方法可在一个反应体系中以高特异性和高灵敏度检测靶 DNA。在均相反应中,靶 DNA 首先被一对 Cas9-单指导 RNA 复合物切割,从而释放出两条带有游离 3'端的单链,允许一对寡核苷酸与这些单链退火。退火的寡核苷酸为从游离 3'端开始的 DNA 聚合提供模板。两条单链的末端因此产生一个通用引物退火位点。然后使用通用引物通过 PCR 扩增靶 DNA。该方法首先通过准确检测 10 种高危型人乳头瘤病毒 (HPV) 的克隆 L1 片段得到验证。然后通过检测两种最高危型 HPV(HPV16 和 HPV18)在 HeLa 和 SiHa 两种 HPV 阳性宫颈癌细胞的基因组 DNA 中的 L1 片段对该方法进行了验证。最后,该方法通过准确检测 30 份临床样本中的 10 种高危型 HPV 进一步得到了验证。